Effects of mefloquine use on Plasmodium vivax multidrug resistance. - RIIP - Réseau International des Instituts Pasteur Access content directly
Journal Articles Emerging Infectious Diseases Year : 2014

Effects of mefloquine use on Plasmodium vivax multidrug resistance.

Nimol Khim
  • Function : Author
  • PersonId : 764211
  • IdRef : 184142334
Jean Popovici
Marc Thellier
Lise Musset


Numerous studies have indicated a strong association between amplification of the multidrug resistance-1 gene and in vivo and in vitro mefloquine resistance of Plasmodium falciparum. Although falciparum infection usually is not treated with mefloquine, incorrect diagnosis, high frequency of undetected mixed infections, or relapses of P. vivax infection triggered by P. falciparum infections expose non-P. falciparum parasites to mefloquine. To assess the consequences of such unintentional treatments on P. vivax, we studied variations in number of Pvmdr-1 (PlasmoDB accession no. PVX_080100, NCBI reference sequence NC_009915.1) copies worldwide in 607 samples collected in areas with different histories of mefloquine use from residents and from travelers returning to France. Number of Pvmdr-1 copies correlated with drug use history. Treatment against P. falciparum exerts substantial collateral pressure against sympatric P. vivax, jeopardizing future use of mefloquine against P. vivax. A drug policy is needed that takes into consideration all co-endemic species of malaria parasites.
Fichier principal
Vignette du fichier
14-0411_FINAL.pdf (546.21 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Licence : CC BY - Attribution

Dates and versions

pasteur-01109696 , version 1 (29-12-2023)





Nimol Khim, Voahangy Andrianaranjaka, Jean Popovici, Saorin Kim, Arsene Ratsimbasoa, et al.. Effects of mefloquine use on Plasmodium vivax multidrug resistance.. Emerging Infectious Diseases, 2014, 20 (10), pp.1637-44. ⟨10.3201/eid2010.140411⟩. ⟨pasteur-01109696⟩
115 View
3 Download



Gmail Facebook X LinkedIn More